Degarelix monotherapy versus luteinizing hormone-releasing hormone (LHRH) agonists plus antiandrogen flare protection in the treatment of men with advanced prostate cancer.

Authors

Bertrand Tombal

Bertrand Tombal

Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Bertrand Tombal , Jan-Erik Damber , Anders Malmberg , Bo-Eric Persson , Laurence Klotz , Peter Iversen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 86)

DOI

10.1200/jco.2014.32.4_suppl.86

Abstract #

86

Poster Bd #

F3

Abstract Disclosures

Similar Posters

First Author: Jan Lehmann

Poster

2016 Genitourinary Cancers Symposium

Incidence of testosterone escape with LHRH agonists in patients receiving radiotherapy for prostate cancer.

Incidence of testosterone escape with LHRH agonists in patients receiving radiotherapy for prostate cancer.

First Author: Derek R Wilke